Category: Publication Spotlight

The Eagle Bioscience’s BI-CAT Adrenaline & Noradrenaline ELISA was highlighted in a recent publication focusing matrix metalloproteinases and stress hormones in lung cancer progression. Check out the full text and abstract below.

Abstract

Several matrix metalloproteinases (MMPs) and psychological stress are associated with poor cancer prognosis. The current work goal was to determine MMPs’ and stress hormones’ blood concentrations from lung adenocarcinoma (LAC) patients. Patients were divided into the following groups: tobacco smokers (TS), wood smoke-exposed (W), passive smokers (PS), TS exposed to wood smoke (TW), and patients with no recognizable risk factor (N). MMPs, tissue inhibitors of metalloproteinases (TIMPs), adrenaline, noradrenaline, and cortisol blood concentrations were measured by ELISA. Zymography and Western blot assays were performed to determine MMP-2 and MMP-9 active and latent forms. MMP-2, MMP-3, MMP-9, and TIMP-1 blood concentrations, and MMP-9 gelatinase activity were augmented, while MMP-12, MMP-14, and TIMP-2 were diminished in LAC patients. Cortisol was increased in LAC samples. Adrenaline concentrations were higher in W, TS, and TW, and noradrenaline was increased in W and N groups. Positive correlations were observed among cortisol and TIMP-1 () and TIMP-2 () in the W group and between noradrenaline and MMP-2 () in the N group. MMPs’ blood concentration increments can be considered as lung cancer progression markers. Although stress hormones were also augmented, only weak correlations were observed between them and MMPs and TIMPs.

Gonzalez-Avila, Georgina, et al. “Matrix Metalloproteinases and Stress Hormones in Lung Cancer Progression.” Journal of Oncology, vol. 2022, 2022, pp. 1–13., https://doi.org/10.1155/2022/5349691.

If you have any questions about the BI-CAT Adrenaline & Noradrenaline ELISA or our other offerings, please contact us here.

The Eagle Bioscience’s Calprotectin ELISA Assay Kit was highlighted in a recent publication focusing on the determination of serum lactate and fecal calprotectin for assessing intestinal inflammation. Check out the full text and abstract below.

Abstract

Since past decades probiotics have been consistently reported to exhibit various health benefits. Probiotics are considered to stabilize the intestinal barrier and epithelial tight junction by modulating the immune functions and further hampering increased permeability disorder observed in inflammatory diseases. Several serological biomarkers such as serum lactate are utilized for determining the conditions of clinical sepsis and intestinal inflammation. Similarly, calprotectin which is also a abundant neutrophil protein found in fecal and plasma sample is responsible for elevating infectious and inflammatory conditions within the patients and rodents. The fecal calprotectin is also used for determining the underlying inflammatory response within the host upon probiotic administration. Both serum lactate and calprotectin serve as markers for the intestinal inflammation for assessing the safety of the probiotic use in the host. The main objective of this chapter is to provide the detailed experimental methods which can be considered while maintaining growth conditions and administration of probiotics within animal models and assessing the serum lactate and calprotectin levels through spectrophotometer, HPLC, and ELISA.

Shah, Firdosh, and Mitesh Kumar Dwivedi. “Determination of Serum Lactate and Fecal Calprotectin for Assessing the Intestinal Inflammation.” Methods and Protocols in Food Science, 2022, pp. 267–275., https://doi.org/10.1007/978-1-0716-2509-5_28.

If you have any questions about the Calprotectin ELISA Assay Kit or our other offerings, please contact us here.

The value of assay-ready cells in providing biologically relevant data for robust therapeutic development.

One of our suppliers, Svar Life Science, was recently featured in an editorial Select Science! This exclusive interview was with Dr. Peter Betz Wolff of the Analytical Development department at AGC Biologics. Dr. Wolff works to implement and develop a range of cell-based assays to meet specific client needs. He shares how his team recommends the use of assay-ready cells to provide the valuable biologically relevant data required for robust pharmaceutical development.

“Compared to non-cell-based approaches, the biggest advantage with cell-based systems is that they are a biologically relevant system, as they include data concerning internal signal cascades.” says Dr. Peter Betz Wolff. “This is of considerable interest to the authorities when reviewing potential new biologics coming to market.”

Check out the full article here.

iLite® Assay Ready Cells are developed by our partners at Svar Life Science. Their iLite technology is based upon a reporter gene assay format, modified and adapted for applications during the whole drug development cycle as well as for monitoring of biological drugs. These cell lines can be developed for any biopharmaceutical target and assays for drug potency, i.e. drug activity, and neutralizing antibodies (NAbs) can easily be set-up using the same cell line. The Assay Ready cells are genetically engineered to be used with a reporter gene assay technique for detection the the drug potency and the NAbs.

Check out our full portfolio of iLite Assay Ready Cells here.

The Eagle Bioscience’s Mouse Albumin ELISA Assay was utilized in a recent publication that focused on how REDD1 ablation attenuates the development of renal complications in diabetic mice. Check out the full text and abstract below.

Abstract

Chronic hyperglycemia contributes to development of diabetic kidney disease by promoting glomerular injury. In this study, we evaluated the hypothesis that hyperglycemic conditions promote expression of the stress response protein regulated in development and DNA damage response 1 (REDD1) in the kidney in a manner that contributes to the development of oxidative stress and renal injury. After 16 weeks of streptozotocin-induced diabetes, albuminuria and renal hypertrophy were observed in wild-type (WT) mice coincident with increased renal REDD1 expression. In contrast, diabetic REDD1 knockout (KO) mice did not exhibit impaired renal physiology. Histopathologic examination revealed that glomerular damage including mesangial expansion, matrix deposition, and podocytopenia in the kidneys of diabetic WT mice was reduced or absent in diabetic REDD1 KO mice. In cultured human podocytes, exposure to hyperglycemic conditions enhanced REDD1 expression, increased reactive oxygen species (ROS) levels, and promoted cell death. In both the kidney of diabetic mice and in podocyte cultures exposed to hyperglycemic conditions, REDD1 deletion reduced ROS and prevented podocyte loss. Benefits of REDD1 deletion were recapitulated by pharmacological GSK3β suppression, supporting a role for REDD1-dependent GSK3β activation in diabetes-induced oxidative stress and renal defects. The results support a role for REDD1 in diabetes-induced renal complications.

Sunilkumar, Siddharth, et al. “Redd1 Ablation Attenuates the Development of Renal Complications in Diabetic Mice.” 2022, https://doi.org/10.2337/figshare.20503266.v1.

If you have any questions about the Mouse Albumin ELISA Assay or our other offerings, please contact us here.

The Eagle Bioscience’s Mouse PD-L1 ELISA Kit was highlighted in a recent publication that explored gene guided OX40L expression on tumor cells to initiate tumor “self-killing”. Check out the full text and abstract below.

Abstract

The low objective response rates and severe side effects largely limit the clinical outcomes of immune checkpoint blockade (ICB) therapy. Here, a tumor “self-killing” therapy based on gene-guided OX40L anchoring to tumor cell membrane was reported to boost ICB therapy. We developed a highly efficient delivery system HA/PEI-KT (HKT) to co-deliver the OX40L plasmids and unmethylated CG-enriched oligodeoxynucleotide (CpG). On the one hand, CpG induced the expression of OX40 on T cells within tumors. On the other hand, OX40L plasmids achieved the OX40L anchoring on the tumor cell membrane to next promote T cells responses via OX40/OX40L axis. Such synergistic tumor “self-killing” strategy finally turned “cold” tumors to “hot”, to sensitize tumors to programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) blockade therapy, and promoted an immune-mediated tumor regression in both B16F10 and 4T1 tumor models, with prevention of tumor recurrence and metastasis. To avoid the side effects, the gene-guided OX40L anchoring and PD-L1 silencing was proposed to replace the existing antibody therapy, which showed negligible toxicity in vivo. Our work provided a new possibility for tumor “self-killing” immunotherapy to treated various solid tumors.

Lin, Lin, et al. “Gene-Guided OX40L Anchoring to Tumor Cells for Synergetic Tumor ‘Self-Killing’ Immunotherapy.” Bioactive Materials, 2022, https://doi.org/10.1016/j.bioactmat.2022.07.008.

If you have any questions about the Mouse PD-L1 ELISA Kit or our other offerings, please contact us here.

The Eagle Bioscience’s 25-OH Vitamin D ELISA Assay was highlighted in a recent publication that explored the relationship between vitamin D and leptin hormones in type 2 diabetes mellitus patients from Kuwait. Check out the full text and abstract below.

Abstract

Background: Type 2 diabetes mellitus (T2DM) and obesity are prevalent in Kuwait. Vitamin D (VD) deficiency and leptin resistance are risk factors for both disorders. A correlation between the two risk factors has been suggested albeit inconsistently reported. Our objective was to determine the effect and association of VD and leptin levels and their related common variants with T2DM.\

Methods: This case-control study included 203 Kuwaiti T2DM patients and 162 healthy Kuwaiti controls. Leptin and VD levels were measured using enzyme linked immunosorbent assays. Genotyping of LEP rs7799039, LEPR rs1137101, VDRrs2228570 and rs731236 was performed using Taqman genotyping assays.

Results: Leptin levels were higher in T2DM patients than controls, but vitamin D levels did not differ. No correlation was found between the levels of the two hormones. VDR rs731236G associated with T2DM risk (Odds ratio 1.66, p=0.0008). VDR haplotype analysis revealed GG/AA, GA/AA or GG/AG to associate with T2DM risk (p=0.01) and increased risk of diabetic neuropathy (p=0.002). VDR rs2228570GG associated with leptin levels in T2DM (p=0.01). Effect of LEP rs7799039 on leptin (p=0.01) and VD levels (p=0.02) was only evident in healthy controls.

Conclusions: VDR rs731236G is associated with T2DM risk in Kuwait, and a VDR haplotype of a less active, low expressing VDR is associated with T2DM and diabetic neuropathy risk. Common variants in leptin and VD related genes appear to mediate the suggested positive correlation of both hormones however their influence is disrupted in T2DM.

Lari F., Alabduljaleel T., Mojiminiyi O., et al. Exploring the Relationship Between Vitamin D and Leptin Hormones in Type 2 Diabetes Mellitus Patients from Kuwait. J Horm Mol Biol Clin Investig. 2022; 10.1515/hmbci-2021-0091

If you have any questions about the 25-OH Vitamin D ELISA Assay or our other offerings, please contact us here.

The Eagle Bioscience’s Free Soluble RANKL ELISA was utilized in a recent publication focusing on Skeletal Disease acquisition in Fibrous Dysplasia. Check out the full text and abstract below.

Abstract

Fibrous dysplasia (FD) is a rare mosaic disorder resulting in fractures, pain, and disability. Bone lesions appear during childhood and expand during skeletal growth. The rate at which FD lesions progress and the biochemical determinants of FD lesion formation have not been established, making it difficult to investigate and implement preventative therapies. The purpose of this study was to characterize FD lesion progression in children, and to identify clinical variables associated with progressive disease. Clinical data and imaging from an ongoing natural history study at the National Institutes of Health (NIH) were reviewed. 99m-Technetium methylene diphosphonate (99Tc-MDP) scans were used to determine Skeletal Burden Score (SBS), a validated quantitative scoring system. FD progression rate was determined by the change in the SBS in each patient per year. Thirty-one children had serial 99Tc-MDP scans, with a median age at first scan of 6 years (interquartile range [IQR] 4–8, range 2–10), and median follow-up 1.1 years (IQR 1.1–2.1, range 0.7–11.2). The median FD progression rate for the total group was 2.12 SBS units/year (IQR 0.81–2.94, range 0.05–7.81). FD progression rates were highest in children under age 8 years and declined with age (p = 0.03). Baseline disease severity was associated with subsequent disease progression (p = 0.009), with the highest FD progression rates in patients with moderate disease (baseline SBS 16–30), and lowest progression rates in those with severe disease (SBS ≥50). Serum levels of the bone formation marker osteocalcin were positively correlated with subsequent FD progression rate (p = 0.01, R = 0.58). There was no association between FD progression and baseline endocrinopathies, fractures, or surgery rates. FD lesions progress during childhood, particularly in younger children and those with moderate involvement. Osteocalcin may potentially serve as a biomarker for progressive disease. These findings may allow clinicians to investigate preventative therapies, and to identify children with FD who are candidates for early interventions. Published 2022. This article is a U.S. Government work and is in the public domain in the USA.

Szymczuk V., Taylor J., Michel Z., Sinaii N., Boyce A.M. Skeletal Disease Acquisition in Fibrous Dysplasia: Natural History and Indicators of Lesion Progression in Children. J Bone Miner Res. 10.1002/jbmr.4618

If you have any questions about the Free Soluble RANKL ELISA or our other offerings, please contact us here.

The Eagle Bioscience’s Secretory IgA ELISA Assay was highlighted in a recent publication focusing on how transcytosis of IgA attenuates salmonella invasion in human enteroids and intestinal organoids. Check out the full text and abstract below.

Abstract

Secretory IgA (SIgA) is the most abundant antibody type in intestinal secretions where it contributes to safeguarding the epithelium from invasive pathogens like the Gram-negative bacterium, Salmonella enterica serovar Typhimurium (STm). For example, we recently reported that passive oral administration of the recombinant monoclonal SIgA antibody, Sal4, to mice promotes STm agglutination in the intestinal lumen and restricts bacterial invasion of Peyer’s patch tissues. In this report, we sought to recapitulate Sal4-mediated protection against STm in human Enteroids and human intestinal organoids (HIOs) as models to decipher the molecular mechanisms by which antibodies function in mucosal immunity in the human gastrointestinal tract. We confirm that Enteroids and HIO-derived monolayers are permissive to STm infection, dependent on HilD, the master transcriptional regulator of the SPI-I type three secretion system (T3SS). Stimulation of M-like cells in both Enteroids and HIOs by the addition of RANKL further enhanced STm invasion. The apical addition of Sal4 mouse IgA, as well as recombinant human Sal4 dimeric IgA (dIgA) and SIgA resulted a dose-dependent reduction in bacterial invasion. Moreover, basolateral application of Sal4 dIgA to Enteroid and HIO monolayers gave rise to SIgA in the apical compartment via a pathway dependent on expression of the polymeric immunoglobulin receptor (pIgR). The resulting Sal4 SIgA was sufficient to reduce STm invasion of Enteroid and HIO epithelial cell monolayers by ~20-fold. Recombinant Sal4 IgG was also transported in the Enteroid and HIOs, but to a lesser degree and via a pathway dependent on the neonatal Fc receptor (FCGRT). The models described lay the foundation for future studies into detailed mechanisms of IgA and IgG protection against STm and other pathogens.

Costello C.M., Willsey G.G., Richards A.F., et al. Transcytosis of IgA Attenuates Salmonella Invasion in Human Enteroids and Intestinal Organoids. Infect Immun. 2022; 90(6). 10.1128/iai.00041-22

If you have any questions about the Secretory IgA ELISA Assay or our other offerings, please contact us here.

The Eagle Bioscience’s Rat KIM-1 ELISA Assay was utilized in a recent publication focusing on the dose-dependent renoprotective impact of Lactoferrin against glycerol-induced rhabdomyolysis and acute kidney injury. Check out the full text and abstract below.

Abstract

Acute kidney injury (AKI) is a clinical disorder with a serious impact on the quality of patients’ lives. Considering its increased worldwide prevalence, investigating novel therapeutic approaches for the management of AKI has been inevitable. Lactoferrin (LF), a glycoprotein belonging to the transferrin family, is known to play an important role in regulating iron homeostasis. This study aimed to evaluate the renoprotective effect of LF (30, 100, and 300 mg/kg orally) against glycerol (GLY)-induced rhabdomyolysis (RM) in rats. RM was induced by a single intramuscular injection of GLY 50% (10 mL/kg) after 24-h water deprivation in male Sprague–Dawley rats. LF administration conferred significant dose-dependent renoprotective impact against GLY-induced RM as evidenced by the decreased renal/somatic index and the significant improvement in renal functions as confirmed by the significant increase in creatinine clearance, decrease in serum creatinine and blood urea nitrogen, and improvement in albuminuria and proteinuria. Redox homeostasis was significantly restored in a dose-dependent manner as well. Moreover, serum interleukin-1β (IL-1β) was significantly decreased with a parallel significant decrease in renal NOD-like receptor family pyrin domain containing 3 (NLRP3) and thioredoxin interacting protein (TXNIP), kidney injury molecule-1 (KIM-1), caspase-3 expression, nuclear factor kappa B (NF-κB), cluster of differentiation (CD68) expression, and a significant increase in renal nuclear factor erythroid 2-related factor 2 (NRF2) expression. Ultimately, LF administration was associated with a significant amelioration of GLY-induced renal necrotic and inflammatory alterations. In conclusion, the observed dose-dependent nephroprotective effect of LF can be attributed to its modulatory impact on inflammatory/apoptotic/oxidative signaling.

Madkour A.H., Helal M.G., Said E., Salem H.A. Dose-Dependent Renoprotective Impact of Lactoferrin Against Glycerol-Induced Rhabdomyolysis and Acute Kidney Injury. Life Sciences. 2022; 302:1. 10.1016/j.lfs.2022.120646

If you have any questions about the Rat KIM-1 ELISA Assay or our other offerings, please contact us here.

The Eagle Bioscience’s Polystreptavidin R Extraordinary High Biotin Binding Capacity was utilized in a recent publication. The researchers of this study were focusing on the use of an aptamer sandwich lateral flow assay (AptaFlow) for antibody-free SARS-CoV-2 detection. Check out the full text and abstract below.

Abstract

The COVID-19 pandemic is among the greatest health and socioeconomic crises in recent history. Although COVID-19 vaccines are being distributed, there remains a need for rapid testing to limit viral spread from infected individuals. We previously identified the SARS-CoV-2 spike protein N-terminal domain (NTD) binding DNA aptamer 1 (SNAP1) for detection of SARS-CoV-2 virus by aptamer–antibody sandwich enzyme-linked immunoassay (ELISA) and lateral flow assay (LFA). In this work, we identify a new aptamer that also binds at the NTD, named SARS-CoV-2 spike protein NTD-binding DNA aptamer 4 (SNAP4). SNAP4 binds with high affinity (<30 nM) for the SARS-CoV-2 spike protein, a 2-fold improvement over SNAP1. Furthermore, we utilized both SNAP1 and SNAP4 in an aptamer sandwich LFA (AptaFlow), which detected SARS-CoV-2 UV-inactivated virus at concentrations as low as 10⁶ copies/mL. AptaFlow costs <$1 per test to produce, provides results in <1 h, and detects SARS-CoV-2 at concentrations that indicate higher viral loads and a high probability of contagious transmission. AptaFlow is a potential approach for a low-cost, convenient antigen test to aid the control of the COVID-19 pandemic.

Yang L.F., Kacherovsky N., Panpradist N., et al. Aptamer Sandwhich Lateral Flow Assay (AptaFlow) for Antibody-Free SARS-CoV-2 Detection. Anal. Chem. 2022: 94:20, 7278–7285. https://doi.org/10.1021/acs.analchem.2c00554

If you have any questions about the Polystreptavidin R Extraordinary High Biotin Binding Capacity or any of our other offerings, please contact us here.